3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Conditions
Colonic Neoplasms
5
Colorectal Neoplasms
3
Carcinoma, Hepatocellular
3
Motor Activity
2
Gastrointestinal Neoplasms
2
Vitamin D Deficiency
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Psychological Well-Being
1
Prostatic Neoplasms
1
Postoperative Complications
1
Pancreatic Neoplasms
1
Osteoporosis
1
Neoplasms
1
Myocardial Ischemia
1
Lung Neoplasms
1
Inflammation
1
Hypertension
1
Heart Diseases
1
Fibrosis
1
Esophageal Neoplasms
1
Coronary Disease
1
Cognitive Dysfunction
1
Cholangiocarcinoma
1
Cardiovascular Diseases
1
Breast Neoplasms
1
Bone Diseases
1
Interventions
Oxaliplatin
295
Capecitabine
209
Fluorouracil
183
Cisplatin
172
Docetaxel
140
S 1 (combination)
135
Paclitaxel
128
Leucovorin
117
Irinotecan
110
pembrolizumab
104
Trastuzumab
76
Nivolumab
59
apatinib
57
Drug Therapy
52
sintilimab
46
Surgical Procedures, Operative
45
Ramucirumab
40
Radiotherapy
40
Bevacizumab
37
Hyperthermic Intraperitoneal Chemotherapy
34
Epirubicin
32
titanium silicide
31
tislelizumab
31
Carboplatin
31
Gastrectomy
28
Cyclophosphamide
27
XELOX
25
Tegafur
24
Folfox protocol
23
Albumin-Bound Paclitaxel
23
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Stomach Neoplasms
×
Vitamin D
×
Gastrointestinal
×
Clear all
NCT04871412
2026-01-30
POISE
Ottawa Hospital Research Institute
Phase 3
Recruiting
20 enrolled